BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang Y, Xiao Z, Guan Z, Zeng Z, Shen Y, Xu X, Zhao C. Bone-seeking nanoplatform co-delivering cisplatin and zoledronate for synergistic therapy of breast cancer bone metastasis and bone resorption. Acta Pharm Sin B 2020;10:2384-403. [PMID: 33354509 DOI: 10.1016/j.apsb.2020.06.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Di W, Shuai Y, Bo W, Wei T, Jinpeng H, Qian G, Deng Y. A bifunctional zoledronate sustained-release system in scaffold: Tumor therapy and bone repair. Colloids Surf B Biointerfaces 2023;222:113064. [PMID: 36481508 DOI: 10.1016/j.colsurfb.2022.113064] [Reference Citation Analysis]
2 Pauk M, Saito H, Hesse E, Taipaleenmäki H. Muscle and Bone Defects in Metastatic Disease. Curr Osteoporos Rep 2022. [PMID: 35994202 DOI: 10.1007/s11914-022-00741-y] [Reference Citation Analysis]
3 Liu Y, Xu Z, Qiao M, Cai H, Zhu Z. Metal-based nano-delivery platform for treating bone disease and regeneration. Front Chem 2022;10:955993. [DOI: 10.3389/fchem.2022.955993] [Reference Citation Analysis]
4 Huang Y, Dai X, Guan Z, Liu D, Ren L, Chen M, Zeng Z, Jiang J, Luo Y, He Y, Huang M, Zhao C. A DNA damage nanoamplifier for the chemotherapy of triple-negative breast cancer via DNA damage induction and repair blocking. Int J Pharm 2022;622:121897. [PMID: 35690308 DOI: 10.1016/j.ijpharm.2022.121897] [Reference Citation Analysis]
5 Pagnotti GM, Trivedi T, Mohammad KS. Translational Strategies to Target Metastatic Bone Disease. Cells 2022;11:1309. [PMID: 35455987 DOI: 10.3390/cells11081309] [Reference Citation Analysis]
6 Shao H, Varamini P. Breast Cancer Bone Metastasis: A Narrative Review of Emerging Targeted Drug Delivery Systems. Cells 2022;11:388. [PMID: 35159207 DOI: 10.3390/cells11030388] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Yu W, Hu C, Gao H. Advances of nanomedicines in breast cancer metastasis treatment targeting different metastatic stages. Adv Drug Deliv Rev 2021;178:113909. [PMID: 34352354 DOI: 10.1016/j.addr.2021.113909] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
8 Jing X, Han J, Zhang J, Chen Y, Yuan J, Wang J, Neo S, Li S, Yu X, Wu J. Long non-coding RNA MEG3 promotes cisplatin-induced nephrotoxicity through regulating AKT/TSC/mTOR-mediated autophagy. Int J Biol Sci 2021;17:3968-80. [PMID: 34671212 DOI: 10.7150/ijbs.58910] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
9 Hermanus Johannes Sliepen S. Bone Cancer Pain, Mechanism and Treatment. Recent Advances in Bone Tumours and Osteoarthritis 2021. [DOI: 10.5772/intechopen.95910] [Reference Citation Analysis]
10 Gu W, Qu R, Meng F, Cornelissen JJLM, Zhong Z. Polymeric nanomedicines targeting hematological malignancies. J Control Release 2021;337:571-88. [PMID: 34364920 DOI: 10.1016/j.jconrel.2021.08.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
11 Qin Y, Tong F, Zhang W, Zhou Y, He S, Xie R, Lei T, Wang Y, Peng S, Li Z, Leong J, Gao H, Lu L. Self‐Delivered Supramolecular Nanomedicine with Transformable Shape for Ferrocene‐Amplified Photodynamic Therapy of Breast Cancer and Bone Metastases. Adv Funct Mater 2021;31:2104645. [DOI: 10.1002/adfm.202104645] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 15.5] [Reference Citation Analysis]
12 Meng X, Wielockx B, Rauner M, Bozec A. Hypoxia-Inducible Factors Regulate Osteoclasts in Health and Disease. Front Cell Dev Biol 2021;9:658893. [PMID: 33816509 DOI: 10.3389/fcell.2021.658893] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]